

ASX Announcement

Third complete response in PTX-200 AML Trial

- **Three patients had total eradication of their cancer (complete response)**
- **AML study to expand with protocol amendment to optimize dosing and schedule of PTX-200 & cytarabine based on recent results**

MELBOURNE Australia, 27 November 2019: Prescient Therapeutics Limited (ASX: PTX) (“Prescient”), a clinical stage company developing personalised medicine approaches to cancer, today announced it would expand its Phase 1b study in patients with acute myeloid leukemia (AML), following an encouraging third complete response (total eradication of disease).

Three of a total of 15 patients experienced complete responses in the study in relapsed or refractory AML patients, which is a difficult to treat cancer population. The three patients had between 25-35mg/m² PTX-200, together with 200-400mg/m² cytarabine.

In consultation with the study investigators, Prescient is making a protocol amendment to change the dosing schedule of PTX-200 in relation to the administration of chemotherapy agent cytarabine with the aim of minimizing overlapping drug interactions. In a previous Phase 1b study in acute leukemias using PTX-200 as a single agent no such side effects were observed, suggesting that the effects seen in the current study may be due to the overlapping interaction of chemotherapy agent cytarabine and PTX-200. Generally, most patients receiving treatment on the study by group have tolerated planned dose levels. Transaminase elevation was observed in three patients, although only one was dose limiting. The amendment will go through usual FDA and ethics committee reviews and the study should be able to re-start enrolment in early 2020.

Prescient’s Chief Medical officer, Dr Terrence Chew said, “The three complete responses observed are very encouraging in a hard to treat patient population. Through this protocol

amendment, we aim to get more patients through more cycles of therapy, with the hope of expanding upon these responses. Our investigators are very supportive of these amendments, as they are encouraged by these results in a patient population that is very difficult to treat and who currently have few treatment options.”

The study is led by world-renowned leukemia expert Professor Jeffrey Lancet at the H. Lee Moffitt Cancer Center in Florida; and also includes Kansas University Medical Center and Yale Cancer Center.

- Ends -

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumors, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials:

- Phase 2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and Florida’s H. Lee Moffitt Cancer Center (Moffitt). PTX-200 showed encouraging efficacy signals in the Phase 1b study, with twice the expected response rate. Responses have demonstrated durability in the study so far.
- Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapsed and refractory Acute Myeloid Leukemia, being conducted the Moffitt; Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.
- Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

Prescient also has a collaboration with Carina Biotech developing new CAR-T therapy approaches.

Find out more at ptxtherapeutics.com, or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/prescient-therapeutics).

For more information please contact:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Andrew Geddes
CityPR
+61 2 9267 4511

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (“Prescient” or the “Company”), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’, ‘expect’, ‘plan’, ‘believe’, ‘guidance’, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management’s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.